argenx SE (NASDAQ:ARGX) Shares Purchased by New York State Common Retirement Fund

New York State Common Retirement Fund increased its holdings in shares of argenx SE (NASDAQ:ARGX) by 15.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 146,168 shares of the company’s stock after purchasing an additional 19,032 shares during the period. New York State Common Retirement Fund owned 0.25% of argenx worth $55,607,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of ARGX. Parkside Financial Bank & Trust acquired a new stake in shares of argenx in the third quarter valued at about $28,000. FNY Investment Advisers LLC purchased a new position in argenx during the 4th quarter valued at about $38,000. Nkcfo LLC increased its holdings in argenx by 22.1% during the 3rd quarter. Nkcfo LLC now owns 116 shares of the company’s stock valued at $57,000 after acquiring an additional 21 shares in the last quarter. CWM LLC increased its holdings in argenx by 29.4% during the 3rd quarter. CWM LLC now owns 207 shares of the company’s stock valued at $102,000 after acquiring an additional 47 shares in the last quarter. Finally, Toronto Dominion Bank increased its holdings in argenx by 174.2% during the 3rd quarter. Toronto Dominion Bank now owns 266 shares of the company’s stock valued at $131,000 after acquiring an additional 169 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenx Trading Up 1.7 %

ARGX stock opened at $375.08 on Wednesday. argenx SE has a 1-year low of $327.73 and a 1-year high of $550.76. The firm has a fifty day moving average price of $386.95 and a two-hundred day moving average price of $419.33.

argenx (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($1.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.45). argenx had a negative net margin of 23.26% and a negative return on equity of 16.97%. The business had revenue of $417.84 million during the quarter, compared to analyst estimates of $378.60 million. During the same period in the previous year, the company posted ($0.70) earnings per share. Equities research analysts expect that argenx SE will post -2.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ARGX has been the subject of several recent research reports. Wedbush restated an “outperform” rating and set a $521.00 target price on shares of argenx in a report on Thursday, April 18th. Robert W. Baird lowered their target price on shares of argenx from $505.00 to $490.00 and set an “outperform” rating for the company in a report on Friday, March 1st. HC Wainwright restated a “buy” rating and issued a $451.00 target price on shares of argenx in a report on Thursday, April 18th. Truist Financial boosted their target price on shares of argenx from $370.00 to $440.00 and gave the company a “buy” rating in a report on Tuesday, March 5th. Finally, Wolfe Research initiated coverage on shares of argenx in a research report on Thursday, February 15th. They set a “peer perform” rating on the stock. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, argenx has a consensus rating of “Moderate Buy” and an average target price of $528.16.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.